Miravant Medical Technologies Inc. (MRVT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Miravant Medical Technologies Inc. (MRVT) trades at $0.00 with AI Score 44/100 (Grade C). Miravant Medical Technologies Inc. is a specialized pharmaceutical company focused on photodynamic therapy for cancer treatment. Market cap: $113,571, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for MRVT: MRVT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MRVT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MRVT: the 1 perspectives are evenly split.
How is this calculated? →Miravant Medical Technologies Inc. (MRVT) Healthcare & Pipeline Overview
Miravant Medical Technologies Inc. specializes in photodynamic therapy, offering innovative treatments for cancer and other serious medical conditions, backed by a robust product pipeline and proprietary light delivery technologies.
What Is the Investment Thesis for MRVT?
Miravant Medical Technologies Inc. presents a unique investment thesis driven by its innovative photodynamic therapy technologies and a diverse pipeline of therapeutic agents. The company's flagship product, PhotoPoint, is positioned to address significant unmet medical needs in cancer treatment, particularly with its potential application in various solid tumors. The ongoing development of PHOTREX and MV9411 could open substantial market opportunities, especially in the ophthalmology and dermatology sectors, which are projected to grow significantly due to increasing prevalence of related diseases. The company's focus on developing proprietary light delivery systems provides a competitive edge in the therapeutic landscape. However, investors may want to evaluate the risks associated with its OTC market status, including limited liquidity and potential regulatory challenges. Monitoring clinical trial outcomes and future financing activities will be crucial for assessing Miravant's growth trajectory.
Based on FMP financials and quantitative analysis
MRVT Key Highlights
- Market Cap: $0.00B, indicating a highly speculative investment environment.
- Beta: -7.25, suggesting significant volatility compared to the market.
- Employee count of 47, reflecting a lean operational structure.
- No dividend yield, indicating a focus on reinvestment rather than shareholder returns.
- Innovative product pipeline with multiple therapeutic agents in various stages of development.
Who Are MRVT's Competitors?
MRVT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CLDX Celldex Therapeutics, Inc. | $38.23 | -0.36% | $2.54B | — |
| BLRX BioLineRx Ltd. | $3.22 | -1.98% | $14.01M | 69 |
| CRMD CorMedix Inc. | $8.68 | -0.80% | $680.96M | 95 |
| XLRN Acceleron Pharma Inc. | $178.75 | +0.00% | 63 | |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MRVT's Key Strengths?
- Innovative photodynamic therapy technology with unique applications.
- Diverse product pipeline addressing multiple therapeutic areas.
- Experienced leadership team with a strong background in pharmaceuticals.
- Established research partnerships enhancing development capabilities.
What Are MRVT's Weaknesses?
- Limited financial resources due to its OTC market status.
- Potential challenges in scaling operations and production.
- Dependence on successful clinical trial outcomes for product validation.
- Small employee base may limit operational capacity.
What Could Drive MRVT Stock Higher?
- Results from ongoing clinical trials for PHOTREX expected in Q4 2026.
- Development of MV9411 for plaque psoriasis showing promising preliminary results.
- Expansion of research partnerships to enhance product pipeline and market reach.
What Are the Key Risks for MRVT?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles may delay product approvals and market entry.
- Limited financial resources may impact operational capabilities and growth.
- Market competition could hinder the adoption of Miravant's therapies.
What Are the Growth Opportunities for MRVT?
- Growth opportunity 1: The global photodynamic therapy market is projected to reach $2.5 billion by 2027, driven by rising cancer prevalence and advancements in technology. Miravant's innovative PhotoPoint system could capture significant market share in oncology, particularly as clinical trials demonstrate its efficacy in treating solid tumors.
- Growth opportunity 2: The aging population is increasing the demand for treatments for age-related diseases, particularly wet AMD. Miravant's PHOTREX product is well-positioned to address this growing need, with the potential to tap into a market expected to exceed $8 billion by 2025, offering substantial revenue growth.
- Growth opportunity 3: MV9411, targeting plaque psoriasis, is entering a market projected to grow at a CAGR of 10% over the next five years. With limited competition in photodynamic treatments for this condition, Miravant could establish a strong foothold and benefit from first-mover advantages.
- Growth opportunity 4: The development of MV0633 for atherosclerosis and related conditions addresses a significant unmet need in cardiovascular health. The cardiovascular drug market is expected to reach $60 billion by 2026, providing Miravant with an opportunity to diversify its portfolio and enhance revenue streams.
- Growth opportunity 5: Expansion into international markets, particularly in Europe and Asia, where the demand for innovative medical therapies is increasing, presents a significant growth opportunity. Miravant's unique technologies could meet the needs of these markets, potentially increasing its global footprint and revenue.
What Opportunities Does MRVT Have?
- Expanding market for photodynamic therapy as cancer rates rise.
- Growing demand for treatments targeting age-related diseases.
- Potential for international expansion into underserved markets.
- Collaborative opportunities with larger pharmaceutical companies.
What Threats Does MRVT Face?
- Intense competition from established pharmaceutical companies.
- Regulatory hurdles in obtaining approval for new therapies.
- Market volatility impacting investor interest and funding.
- Rapid technological advancements may outpace current offerings.
What Are MRVT's Competitive Advantages?
- Innovative technology in photodynamic therapy provides a competitive edge.
- Strong focus on research and development fosters unique product offerings.
- Proprietary light delivery systems differentiate Miravant from competitors.
- Niche market positioning in specialized therapeutic areas reduces direct competition.
- Established intellectual property rights protect innovations and market position.
What Does MRVT Do?
Miravant Medical Technologies Inc. was founded in 1989 as PDT, Inc., and later rebranded in September 1997 to its current name. Headquartered in Santa Barbara, California, the company is dedicated to pharmaceutical research and development, focusing on photodynamic therapy (PDT) to treat various diseases. A cornerstone of its offerings is the PhotoPoint system, which utilizes light to activate therapeutic agents that target and eradicate cancerous cells. Miravant's product pipeline includes several promising therapeutic agents: PHOTREX, aimed at treating wet age-related macular degeneration (AMD); MV9411, a photoreactive compound for managing plaque psoriasis; MV0633, which targets atherosclerosis and related conditions; MV2101, designed for vascular access graft disease in hemodialysis patients; and MV6401, a treatment for solid tumors currently under development. The company's innovative approach to drug delivery and therapy positions it uniquely within the healthcare sector, particularly in the niche of photodynamic therapies. Miravant's commitment to advancing medical technology is evident in its ongoing research and development efforts, which aim to improve patient outcomes and expand treatment options in oncology and dermatology.
What Products and Services Does MRVT Offer?
- Develops photodynamic therapy technologies for cancer treatment.
- Manufactures light-generating and light-delivery devices essential for therapies.
- Offers a diverse pipeline of therapeutic agents targeting various medical conditions.
- Focuses on innovative solutions for age-related diseases and dermatological conditions.
- Conducts research and development to advance medical technology.
- Operates within the healthcare sector, specifically in drug manufacturing.
How Does MRVT Make Money?
- Generates revenue through the development and commercialization of innovative therapeutic agents.
- Manufactures proprietary devices that complement its drug therapies.
- Engages in partnerships and collaborations to enhance research and development capabilities.
- Focuses on clinical trials to validate the efficacy and safety of its products.
- Seeks funding and investment to support ongoing research and development efforts.
What Industry Does MRVT Operate In?
The healthcare sector, particularly the drug manufacturing industry, is experiencing rapid growth driven by advancements in biotechnology and increasing demand for specialized treatments. The global photodynamic therapy market is projected to expand significantly, fueled by rising incidences of cancer and eye diseases. Miravant Medical Technologies Inc. operates within this dynamic landscape, focusing on innovative therapies that leverage light-based technologies. As competition intensifies among pharmaceutical firms, Miravant's unique approach to photodynamic therapy positions it as a potential leader in this niche market, although it must navigate challenges related to market entry and regulatory approvals.
Who Are MRVT's Key Customers?
- Healthcare providers and hospitals seeking advanced treatment options.
- Patients suffering from cancer and other serious medical conditions.
- Pharmaceutical partners interested in collaboration for drug development.
- Investors looking for opportunities in innovative healthcare solutions.
- Regulatory bodies requiring compliance with medical standards and safety.
F-Score 2/9Financial Health
Miravant Medical Technologies Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
MRVT Valuation & Market Position
With a 114K market cap, Miravant Medical Technologies Inc. sits in the micro-cap segment of the market. Relative to its peer group, MRVT's quantitative score of 44/100 is below the peer average of 74/100.
ROE 353%Key Financial Metrics
Return on equity for Miravant Medical Technologies Inc. stands at 352.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 3.45 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Miravant Medical Technologies Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Santa Barbara, US. The company is led by CEO David E. Mai. MRVT has traded publicly since 1995.
MRVT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative photodynamic therapy technology with unique applications.
- Diverse product pipeline addressing multiple therapeutic areas.
- Experienced leadership team with a strong background in pharmaceuticals.
- Established research partnerships enhancing development capabilities.
Bear Case
- Limited financial resources due to its OTC market status.
- Potential challenges in scaling operations and production.
- Dependence on successful clinical trial outcomes for product validation.
- Small employee base may limit operational capacity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MRVT Latest News
No recent news available for MRVT.
MRVT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MRVT.
Price Targets
Wall Street price target analysis for MRVT.
MRVT MoonshotScore
What does this score mean?
The MoonshotScore rates MRVT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David E. Mai
CEO
David E. Mai has extensive experience in the pharmaceutical industry, having led various initiatives in drug development and commercialization. He holds a degree in biochemistry and has worked in both corporate and startup environments, focusing on innovative healthcare solutions. His leadership has been pivotal in driving Miravant's strategic direction and fostering a culture of innovation.
Track Record: Under David E. Mai's leadership, Miravant has made significant strides in developing its product pipeline, particularly in photodynamic therapies. His strategic decisions have positioned the company to explore new therapeutic areas and expand its market reach.
MRVT OTC Market Information
The OTC Other tier includes companies that trade on the over-the-counter market but do not meet the requirements for higher tiers such as OTCQX or OTCQB. This tier is typically associated with companies that may have limited financial reporting and lower trading volumes compared to those on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity can lead to difficulties in buying or selling shares.
- Less stringent reporting requirements may result in less transparency.
- Higher volatility due to lower trading volumes can impact stock price stability.
- Potential for regulatory scrutiny as an OTC company may affect operations.
- Review clinical trial results and their implications for product development.
- Assess the company's financial health and funding requirements.
- Monitor regulatory developments and potential approval timelines.
- Evaluate the competitive landscape and market positioning.
- Investigate partnerships and collaborations that may enhance growth.
- Established history since 1989 with a focus on innovative therapies.
- Active engagement in clinical trials and research activities.
- Strong leadership team with relevant industry experience.
Miravant Medical Technologies Inc. Healthcare Stock: Key Questions Answered
What does Miravant Medical Technologies Inc. do?
Miravant Medical Technologies Inc. specializes in developing innovative photodynamic therapies aimed at treating various medical conditions, particularly cancer and age-related diseases. The company manufactures essential light-generating and light-delivery devices that are integral to its therapies, and it has a diverse pipeline of therapeutic agents targeting conditions such as wet age-related macular degeneration, plaque psoriasis, and atherosclerosis.
What is Miravant Medical Technologies Inc.'s drug pipeline status?
Miravant Medical Technologies Inc. has a robust drug pipeline that includes several therapeutic agents at various stages of development. Key products include PHOTREX for wet age-related macular degeneration, MV9411 for plaque psoriasis, and MV0633 targeting atherosclerosis. The company is actively conducting clinical trials to validate these therapies, with upcoming results expected in late 2026.
What are the main risks for MRVT?
Miravant Medical Technologies Inc. faces several risks, including regulatory hurdles that may delay product approvals and market entry, limited financial resources that could impact its operational capabilities, and ongoing competition from established pharmaceutical companies. Additionally, the company's OTC market status may lead to liquidity challenges and increased volatility in its stock price.
What are the key factors to evaluate for MRVT?
Miravant Medical Technologies Inc. (MRVT) holds an AI score of 44/100 (low). Not financial advice.
How frequently does MRVT data refresh on this page?
MRVT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MRVT's recent stock price performance?
Miravant Medical Technologies Inc. (MRVT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative photodynamic therapy technology with unique applications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MRVT overvalued or undervalued right now?
Valuing Miravant Medical Technologies Inc. (MRVT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MRVT?
Before investing in Miravant Medical Technologies Inc. (MRVT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of June 2026.